| Literature DB >> 25186949 |
Brian D Crompton1, Chip Stewart2, Amaro Taylor-Weiner2, Gabriela Alexe3, Kyle C Kurek4, Monica L Calicchio4, Adam Kiezun2, Scott L Carter2, Sachet A Shukla5, Swapnil S Mehta1, Aaron R Thorner1, Carmen de Torres6, Cinzia Lavarino6, Mariona Suñol6, Aaron McKenna2, Andrey Sivachenko2, Kristian Cibulskis2, Michael S Lawrence2, Petar Stojanov7, Mara Rosenberg2, Lauren Ambrogio2, Daniel Auclair2, Sara Seepo2, Brendan Blumenstiel2, Matthew DeFelice2, Ivan Imaz-Rosshandler8, Angela Schwarz-Cruz Y Celis8, Miguel N Rivera9, Carlos Rodriguez-Galindo1, Mark D Fleming4, Todd R Golub10, Gad Getz11, Jaume Mora6, Kimberly Stegmaier12.
Abstract
UNLABELLED: Pediatric Ewing sarcoma is characterized by the expression of chimeric fusions of EWS and ETS family transcription factors, representing a paradigm for studying cancers driven by transcription factor rearrangements. In this study, we describe the somatic landscape of pediatric Ewing sarcoma. These tumors are among the most genetically normal cancers characterized to date, with only EWS-ETS rearrangements identified in the majority of tumors. STAG2 loss, however, is present in more than 15% of Ewing sarcoma tumors; occurs by point mutation, rearrangement, and likely nongenetic mechanisms; and is associated with disease dissemination. Perhaps the most striking finding is the paucity of mutations in immediately targetable signal transduction pathways, highlighting the need for new therapeutic approaches to target EWS-ETS fusions in this disease. SIGNIFICANCE: We performed next-generation sequencing of Ewing sarcoma, a pediatric cancer involving bone, characterized by expression of EWS-ETS fusions. We found remarkably few mutations. However, we discovered that loss of STAG2 expression occurs in 15% of tumors and is associated with metastatic disease, suggesting a potential genetic vulnerability in Ewing sarcoma. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25186949 DOI: 10.1158/2159-8290.CD-13-1037
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397